Sugary drinks linked to earlier onset of menstrual periods
Two days ago, we reported that puberty comes earlier for girls, thanks to EDCs and phthalates exposure. According to another research. girls who frequently consume sugary drinks also tend to start their menstrual periods earlier than girls who do not, The findings are important not only because of the growing problem of childhood obesity in a number of developed countries, but also because starting periods earlier is linked to an increased risk of breast cancer later in life.
Harvard Medical School researchers found that the girls who drank more than 1.5 daily servings of sugar-added drinks (not fruit juices) started their periods an average of 2.7 months earlier than girls who had been drinking fewer than two servings of such drinks a week. This should not be overlooked, because unlike most other predictors of a girl’s age at her first period, sugar-sweetened drinks consumption is something people can change,
Interview de la présidente de l’APESAC, Marine Martin, sur le combat pour la reconnaissance de l’embyrofoetopathie au valproate
Interview de la présidente de l’APESAC, Marine Martin, sur le combat pour la reconnaissance de l’embyrofoetopathie au valproate. Avec Aurelie Renard, présentatrice du JT sur le plateau de France3 Languedoc-roussillon.
En savoir plus
Vidéo publiée le 31 Jan 2015 par la chaine APESAC.
” David Kessler, the former U.S. Food and Drug Administration commissioner, testified Wednesday that as a pediatrician, it “certainly is a red flag to me” that a Janssen Pharmaceuticals Inc. study of the use of its antipsychotic drug Risperdal in young children and adolescents, mainly boys, showed high rates of breast growth.
Risperdal was originally approved in 1993 only to treat psychotic disorders in adults. “On March 3, 2002, the approved use was narrowed to treatment of schizophrenia only,” phrasing used by the Justice Department in 2013 in its statement after J&J agreed to pay $2.2 billion for settle one criminal charge and other allegations that it illegally promoted Risperdal for unapproved uses.
Doctors are allowed to prescribe medicine as they see fit, including “off-label,” meaning for conditions not approved by the FDA and on the official label. Drug companies are not supposed to promote drugs for illnesses or for a group of patients for whom the drug is not approved and not on the label. But the squishiness of definitions of mental illness opens the door even wider for drug companies do such promotion. ”
Read more via the links below…
Sources and more information
Mother brought to tears hearing Johnson & Johnson’s Risperdal tactics, phillypharma, January 30, 2015.
Former FDA chief testifies for plaintiff in Risperdal case, phillypharma, January 28, 2015.
Risperdal Male Breast Growth Class Action Lawsuit Settlement Claims & Lawyers 2014, nationalinjuryhelp, 2015.
J&J’s $2.2 Billion Settlement Won’t Stop Big Pharma’s Addiction To Off-Label Sales, forbes, 11/12/2013
It is currently unknown how effective it may be, or what the short- or long-term consequences are
A modelling study estimated the three-person IVF technique, currently illegal, could be used for thousands of women with genes linked to serious mitochondrial DNA diseases.
There was an initial debate on mitochondrial donation in the House of Commons on the 1st of September 2014. The Muscular Dystrophy Campaign, Newcastle University, The Lily Foundation and Wellcome Trust are organising a drop-in MP briefing session on Tuesday 3rd February from 12.30pm to 2pm in Committee Room 10.
The three-person IVF is designed to prevent babies being born with mitochondrial conditions by usinge healthy mitochondria from a donor egg to replace the mitochondria in the mother’s egg, either before fertilisation or just after, to prevent passing on mutations.
The study estimated almost 2,500 women of child-bearing age in the UK, and almost 12,500 women in the US could benefit from the new IVF technique. As this technique is untried, it is currently unknown how effective it may be, or what the short- or long-term consequences are.
Sources and more information
Mitochondrial Donation — How Many Women Could Benefit?, NEJM, 2015DOI: 10.1056/NEJMc1500960, January 28.
Two and a half thousand women could benefit from mitochondrial donation in the UK, Newcastle University, 28th January 2015.
Thousands of UK women could benefit from ‘three-person’ IVF, NHS Choices, January 29 2015.
Leading figures express support for mitochondrial donation, Wellcome Trust, 29 JAN, 2015.
Consequences of in utero DES exposure on the breast may be mediated by proliferative effects of estrogen
In 1992, the National Cancer Institute (NCI) established the Continuation of Follow-Up of DES-Exposed Cohorts to study the long-term health effects of exposure to Diethylstilbestrol (DES) . Genetic effects on human breast tissue have not been examined. The authors investigated whether breast tissue of women exposed in utero to DES might exhibit the genetic abnormalities that characterize other DES-associated tumors.
Subjects enrolled in the NCI Cohort were queried about breast biopsies or breast cancer diagnoses. Available tissue blocks were obtained for invasive cancers (IC), in situ cancers (CIS), or atypical hyperplasia (AH). Exposure status was blinded, lesions were microdissected, and their DNA was analyzed for microsatellite instability (MI) and loss of heterozygosity (LOH), or allele imbalance (AI), at 20 markers on 9 chromosome arms.
From 31 subjects (22 exposed, 9 unexposed), 273 samples were analyzed (167 normal epithelium, 16 AH, 30 CIS, 60 IC). Exposed and unexposed subjects exhibited no differences in breast cancer risk factors or demographic characteristics, except for age at diagnosis (exposed vs. unexposed: 43.2 vs. 48.8 years of age, P = .02). The authors found that MI was rare and that AI was common, with frequencies consistent with previous reports. The global age-adjusted relative rate (RR) of AI was 1.3, 95% CI = 0.8-2.4. No statistically significant associations were observed after adjustment for risk factors or after stratification by histology or by chromosome arm.
In utero DES exposure does not appear to significantly increase genomic instability in breast epithelium, as measured by MI and AI. Breast tissue may respond differently from that of the reproductive tract to in utero DES exposure. Consequences of in utero DES exposure on the breast may be mediated by proliferative effects of estrogen.
Sources and full study
In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium, NCBIPMID: 16998936, Cancer. 2006 Nov 1;107(9):2122-6.
Reminding people of the importance of smear tests by sharing your lipstick smear selfie for Cervical Cancer Prevention Week
What is #SmearForSmear?
Smear tests (cervical screening) save 5,000 lives a year yet one in five women who are eligible to attend do not take up their invitation.
For young women aged 25-29 this rises to one in three.
#SmearForSmear allows you to remind people of the importance of smear tests by sharing your lipstick smear selfie and nominating your friends to do the same.
Together we can help prevent cervical cancer.
Put on your lipstick.
Smear your lipstick and take a selfie.
Use #SmearForSmear and @JoTrust then nominate a friend.